联合应用埃索美拉唑、铝碳酸镁和莫沙比利治疗难治性胃食管反流病

目的:探讨联合应用埃索美拉唑、铝碳酸镁和莫沙比利治疗难治性胃食管反流病(r-GERD)的临床疗效.方法:101例rGERD患者随机为A(n=36),B(n=34)和C组(n=31),分别采用埃索美拉唑 铝碳酸镁 莫沙比利、埃索美拉唑 莫沙比利及铝碳酸镁 莫沙比利治疗.4及8 wk后评价临床症状,8 wk后评价内镜下有效率.结果:治疗4 wk后,A,B和C组临床症状总改善率分别为88.9%,79.4%和61.3%,A组与B,C两组相比差异显著(χ2=7.3531,P＜0.05).治疗8 wk后,A,B和C组临床症状总改善率分别为97.2%,88.2%和71.0%,内镜下有效率分别为94.4%,85.3%和67.7%,A组临床症状总改善率和内镜下有效率与B,C组相比存在显著性差异(χ2=9.6079,P＜0.01;χ2=8.6496,P＜0.05).结论:埃索美拉唑联合铝碳酸镁和莫沙比利治疗rGERD有很高的临床疗效.

Efficacy of esomeprazole combined with hydrotalcite and mosapride in treatment of refractory gastroesophageal reflux disease

AIM: To evaluate the effect of esomeprazole combined with hydrotalcite and mosapride on refractory gastroesophageal reflux disease (rGERD). METHODS: A total of 101 rGERD patients were randomly divided into groups A (n = 36), BB(n = 34) and C (n = 31), treated with esomeprazole plus hydrotalcite plus mosapride, esomeprazole plus mosapride, and hydrotacite plus mosapride, respectively. The clinical outcomes were observed and analyzed after 4 and 8 weeks of treatment. Endoscopy was performed to evaluate the effective rate in the three groups. RESULTS: After 4 weeks of treatment, the total improvement rate was significantly higher in group A (88.9%) than that in group B (79.4%) and C (61.3%) (X2 = 7.3531, P < 0.05). Eight weeks after treatment, the total improvement rates were 97.2%, 88.2% and 71.0% in group A, B and C, ,and the effective rates detected by endoscopy were 94.4%, 85.3% and 67.7%, respectively. The total improvement rate (X2 = 9.6039, P < 0.01) and effective rate (X2 = 8.6496, P < 0.05) were markedly higher in group A than those in B and C group. CONCLUSION: Esomeprazole combined with hydrotalcite and mosapride may be highly effective in the treatment of rGERD.